Resources Repository
-
OrganizationWeb Portal 2024ISPOR
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics …
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) exists to advance the policy, science, and practice of pharmacoeconomics (health economics) and health outcomes research. ISPOR publishes Value in Health, which contains original research articles in the areas of economic evaluation, outcomes research, and conceptual, methodological, and health policy articles. Beyond health economics and outcomes research resources, tools of ISPOR include strategic initiatives, publications, and member…
Mathematical Models | Costing Methods | Health Outcomes | Value of Information | Health/Medicine | Business/Industry | Economics/Finance | Child/Nutrition | Preferences/Values | Priority Setting/Ethics | Cost-Effectiveness Analysis | Technology Assessment | Operations Research | Infectious Diseases | Maternal/Reproductive Health | Chronic Disease/Risk | Health Systems | Policy/Regulation | Science/Technology | Global -
ArticlePublication 2018Equity Impact Vaccines May Have on Averting Deaths and Medical Impoverishment
In this analysis, authors estimated the number of deaths averted and the number of cases …
In this analysis, authors estimated the number of deaths averted and the number of cases of medical impoverishment averted of ten antigens and their corresponding vaccines across income quintiles for forty-one low- and middle-income countries. The study found that vaccines administered between 2016 and 2030 would prevent 36 million deaths. Vaccines will have the greatest impact on reducing cases of poverty caused by hepatitis B, helping an estimated 14 million people avoid medical impoverishment. An…
Mathematical Models | Costing Methods | Health Outcomes | Health/Medicine | Economics/Finance | Child/Nutrition | Priority Setting/Ethics | Cost-Effectiveness Analysis | Infectious Diseases | Global Governance | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Asia & Pacific -
OrganizationWeb Portal 2024Agency for Healthcare Research and Quality (AHRQ)
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for …
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for research on health care quality, costs, outcomes and patient safety. AHRQ is the health services research arm of the U.S. Department of Health and Human Services (HHS), complementing the biomedical research mission of its sister agency, the National Institutes of Health. The agency is home to research centers that specialize in major areas of health care research, including: clinical practice…
Test Performance | Costing Methods | Health Outcomes | Health/Medicine | Economics/Finance | Child/Nutrition | Decision Analysis | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Maternal/Reproductive Health | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Government/Law | Science/Technology | North America -
ArticlePublication 2015Extended Cost-Effectiveness Analysis of Treatment and Prevention of Diarrhoea in Ethiopia
This article, published in BMJ Open, aims to illustrate the size and distribution of benefits …
This article, published in BMJ Open, aims to illustrate the size and distribution of benefits due to the treatment and prevention of diarrhoea (i.e., rotavirus vaccination) in Ethiopia. The authors use an economic model to examine the impacts of universal public finance (UPF) of diarrhoeal treatment alone, as opposed to diarrhoeal treatment along with rotavirus vaccination using extended cost-effectiveness analysis (ECEA). The study finds that diarrhoeal treatment paired with rotavirus vaccination is more cost effective…
Costing Methods | Health Outcomes | Health/Medicine | Climate/Environment | Economics/Finance | Child/Nutrition | Priority Setting/Ethics | Cost-Effectiveness Analysis | Infectious Diseases | Social Determinants | Environmental Health | Health Systems | Sub-Saharan Africa -
ArticlePublication 2017Reduced Burden of Childhood Diarrheal Diseases through Increased Access to Water and Sanitation in India: Modeling Analysis
This analysis estimates the health and economic benefits of scaling up the coverage of piped …
This analysis estimates the health and economic benefits of scaling up the coverage of piped water and improved sanitation to a near-universal 95% level among Indian households. The authors used an agent-based microsimulation platform, IndiaSim, to model disease progression and individual healthcare-seeking behavior in India, and use ECEA to estimate health and economic outcomes over time. They found that scaling up access to piped water and improved sanitation could avert 43,352 diarrheal episodes and 68…
Costing Methods | Health Outcomes | Health/Medicine | Economics/Finance | Child/Nutrition | Priority Setting/Ethics | Microsimulation | Cost-Effectiveness Analysis | Social Determinants | Environmental Health | Energy/Engineering | Science/Technology | Asia & Pacific -
OrganizationWeb Portal 2024Results for Development
Results for Development (R4D) was founded in 2008, with a mission to create self-sustaining systems …
Results for Development (R4D) was founded in 2008, with a mission to create self-sustaining systems that support health, educated people, while ensuring that local change agents are in the driver’s seat, and that knowledge is transformed into action. Their work supports sustainable progress in health, education and nutrition, and puts data users at the center of all efforts. They develop tools - including dashboards, scorecards and performance metrics - in a way that is designed to solve practical…
Evidence Synthesis | Costing Methods | Health/Medicine | Climate/Environment | Child/Nutrition | Priority Setting/Ethics | Technology Assessment | Infectious Diseases | Health Systems | Education/Labor | Global -
ArticlePublication 2010Health and Economic Impact of Rotavirus Vaccination in GAVI-Eligible Countries
Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately …
Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Motivated by the global recommendation by the WHO that all countries include infant rotavirus vaccination in their national immunization programs, the objective of this analysis was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. The authors synthesized population-level data from various sources (primarily from…
Mathematical Models | Health Outcomes | Health/Medicine | Economics/Finance | Child/Nutrition | State-Transition | Cost-Effectiveness Analysis | Infectious Diseases | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
OrganizationWeb Portal 2024Immunization Costing Action Network (ICAN)
The Immunization Costing Action Network (ICAN) aims to increase the availability, understanding, and use of …
The Immunization Costing Action Network (ICAN) aims to increase the availability, understanding, and use of immunization delivery cost information. They are building country capacity around the generation of cost information to solve program and policy challenges and working with countries to improve interpretation and translation of cost information for country decision-making processes and routine planning and budgeting. The ICAN is comprised of four-member countries (India, Indonesia, Tanzania, and Vietnam) with country teams that include health…
Costing Methods | Health/Medicine | Business/Industry | Economics/Finance | Child/Nutrition | Infectious Diseases | Health Systems | Science/Technology | Global -
ArticlePublication 2016Cost-Effectiveness of Routine Vaccination With a Live-Attenuated Dengue Vaccine: Model Comparison
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, …
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 months following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. This paper reports predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine…
Mathematical Models | Health/Medicine | Climate/Environment | Economics/Finance | Child/Nutrition | Dynamic Transmission | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Global Governance | Latin America & Caribbean | Asia & Pacific